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 Angiopoietin-like 4 (Angptl4) is a multifunctional pro-
tein involved in plasma triglyceride (TG) metabolism ( 1 ), 
energy metabolism ( 2, 3 ), tumor survival ( 4 ), metastasis 
( 5, 6 ), angiogenesis ( 7, 8 ), wound healing ( 9 ), infl amma-
tion ( 10 ), and nephrotic syndrome ( 11 ). It is expressed in 
a wide variety of tissues, with highest expression displayed 
in the liver . Angptl4 is a secretory protein, but a signifi cant 
amount is retained at the cell surface attached to gly-
cosaminoglycans and can be released after heparin treat-
ment in vitro and in vivo ( 12, 13 ). Interaction of Angptl4 
with proteoglycans protects it from proteolysis by propro-
tein convertases ( 14 ). Secreted Angptl4 is cleaved at a spe-
cifi c site, generating the N-terminal and C-terminal 
fragments that together with the full-length protein, can 
be detected in plasma associated with different lipopro-
tein classes ( 15 ). 
 Abstract  Animal studies have suggested that angiopoietin-
like 4 (Angptl4) regulates adiposity through central and pe-
ripheral mechanisms. The aim of this study was to investigate 
whether serum concentration and adipose tissue expression 
of Angptl4 are associated with obesity-related parameters in 
humans. Altogether, 75 dizygotic (DZ) and 46 monozygotic 
(MZ) twin pairs were studied, from the FinnTwin12 and 
FinnTwin16 cohorts. Among the MZ pairs, 21 were discor-
dant for body mass index (BMI) (intra-pair BMI-difference 
>2.5 kg/m 2 , age 23–33 years). Serum Angptl4 (s-Angptl4) 
levels were measured by ELISA, and adipose tissue gene ex-
pression was analyzed by genome-wide transcript profi ling. 
In MZ twin pairs discordant for BMI, s-Angptl4 and adipose 
tissue  ANGPTL4 mRNA (at- ANGPTL4 ) levels were signifi -
cantly decreased ( P = 0.04 and  P = 0.03, respectively) in 
obese twins as compared with their nonobese cotwins. In all 
twins, intra-pair differences in s-Angptl4 levels were in-
versely correlated with intra-pair differences in BMI ( r = 
  0.27,  P = 0.003). In individual MZ twins, at- ANGPTL4 ex-
pression was inversely correlated with BMI ( r =   0.44,  P = 
0.001) and positively correlated with at- LIPE ( r = 0.24,  P = 
0.01) and at- ABHD5 ( r = 0.41,  P = 0.005) expression.  Our 
results demonstrated that variation in Angptl4 concentra-
tion was only modestly accounted for by genetic factors and 
suggest a role for Angptl4 in acquired obesity in humans .—
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cordant for obesity. The subjects provided written informed con-
sent. The protocol was designed and performed according to the 
principles of the Helsinki Declaration and was approved by the 
Ethical Committee of the Helsinki University Central Hospital. 
 Metabolic measurements 
 Plasma glucose was measured using the spectrophotometric 
hexokinase and glucose-6-phosphate dehydrogenase assay and 
serum insulin with time-resolved immunofl uorometric assay 
(Perkin Elmer). Serum HDL cholesterol (HDL-C) and TG con-
centrations were determined using enzymatic methods (Roche 
Diagnostics Hitachi), and LDL-cholesterol (LDL-C) was calcu-
lated using the Friedewald formula ( 27 ). Serum free fatty acids 
(FFAs) were quantifi ed using a kit from Zen-Bio, Inc. 
 Serum samples for Angptl4, Angptl3, and FGF21 analysis were 
stored at  2 80°C until analyzed. S-Angptl4, Angptl3, and FGF21 
levels were measured using ELISAs, as previously described ( 13, 
25 ). The Angptl4 ELISA recognizes full-length Angptl4 in hu-
man plasma ( 28 ). 
 Adipose tissue transcriptomics 
 Subcutaneous adipose tissue biopsies were obtained from 
22 MZ twin pairs, 17 of which were discordant for BMI. Fat biop-
sies were collected under local anesthesia using a surgical technique 
and snap-frozen in liquid nitrogen for later processing. Total 
RNA was extracted using the RNeasy Lipid Mini Kit (Qiagen) ac-
cording to the manufacturer’s instructions. The quality of the 
RNA was analyzed using the 2100 Bioanalyzer platform (Agilent 
Technologies) prior to proceeding to array. Two micrograms of 
total RNA were treated according to conventional Affymetrix eu-
karyotic RNA labeling protocols (Affymetrix; Santa Clara, CA), 
followed by biotin labeling and fragmentation of the cRNA ac-
cording to standard protocol. Hybridization, staining, and wash-
ing of the Affymetrix U133 Plus 2.0 chips were performed using 
the Affymetrics Fluidics Station 450 and Hybridization Oven 640 
under standard conditions. The scanning of the chips was done 
using the Affymetrix GeneChip Scanner 3000. Raw expression 
values were normalized using the Robust Multi-array Average 
(RMA) with the help of probe sequence and with GC-content 
background correction (GCRMA algorithm) and analyzed using 
the GeneSpring GX 7.3 software (Agilent Technologies). 
 Statistical analyses 
 Statistical analyses were performed using SPSS version 17.0 for 
Windows (SPSS, Inc.), Stata statistical software (release 11.0; 
Stata Corporation, College Station, TX) and GraphPad Prism 
4.03 (GraphPad Software, Inc.). All parameters were log10 trans-
formed before they were used in statistical analyses. In individual 
twins, the relationships between serum concentrations or adi-
pose tissue mRNA levels of Angptl4 with other measured param-
eters, Pearson correlations with  P values corrected for clustered 
sampling of cotwins within-pairs were used. Comparisons be-
tween the cotwins were made by paired  t -test. Within-pair differ-
ences of the measures were calculated by subtracting the leaner 
cotwin’s value from the heavier cotwin’s value. Pearson correla-
tions of the within-pair differences were calculated to assess the 
relationships of the measures fully (in MZ) or partially (in DZ) 
adjusted for genetic infl uences. 
 To estimate the heritability of Angptl4 and FGF21, we assessed 
twin similarity within each zygosity group using intra-class corre-
lations (ICCs) and biometric methods using the Mx statistical 
package (6th ed., Richmond, VA), as previously described ( 25 ). 
Preliminary information on the potential infl uence of factors un-
derlying Angptl4 and FGF21 protein levels was obtained by com-
paring the ICC between MZ and DZ twins. A higher within-pair 
 The most-characterized function of Angptl4 is the inhi-
bition of lipoprotein lipase (LPL) ( 16 ), an effect observed 
both in vitro and in vivo. Inhibition of LPL by Angptl4 
causes elevated plasma TG levels in mice ( 17 ). These stud-
ies are supported by genetic studies in humans that have 
revealed mutations in ANGPTL4 to be associated with cir-
culating TG levels ( 18, 19 ). 
 The role of Angptl4 in obesity has been intensely inves-
tigated in mouse models. For example, germ-free mice are 
protected against diet-induced obesity resulting from an 
increased expression of intestinal Angptl4, which is sup-
pressed by gut microbiota in normal mice ( 20 ). Also, 
Angptl4 has been reported to be a powerful signal from fat 
and other tissues to prevent fat storage and stimulate fat 
mobilization. Angptl4 overexpression caused a 50% reduc-
tion in adipose tissue weight by stimulating lipolysis, FA 
oxidation, and uncoupling in fat ( 2, 15 ). It has further 
been suggested that Angptl4 has an important role in cen-
tral regulation of energy metabolism ( 3 ). Intracerebroven-
tricular administration of Angptl4 suppressed food intake 
and body weight gain, and enhanced energy expenditure, 
whereas Angptl4-null mice displayed increased body 
weight, but reduced energy expenditure ( 3 ). 
 Regarding the role of Angptl4 in human obesity, very 
little data are available. In a previous study from our group, 
we were able to show that serum Angptl4 (s-Angptl4) levels 
were decreased in overweight subjects as compared with 
normal-weight subjects ( 13 ). To further evaluate the rela-
tionship between Angptl4 and acquired human obesity, 
we performed a study in young twin pairs discordant for 
body mass index (BMI), with one twin weighing >2.5 kg/
m 2 more than the other. This study represents a more-
detailed analysis of the role of Angptl4 in acquired human 
obesity, irrespective of genetic background, age, and gen-
der. We also studied the relationship between Angptl4 and 
fi broblast growth factor 21 (FGF21), a fasting-induced 
hormone that shares similarities in gene regulation ( 21–
23 ) and has been reported to correlate with s-Angptl4 lev-
els ( 24 ), as well as Angptl3, a structurally related protein 
that does not correlate with s-Angptl4 levels ( 13 ). 
 MATERIALS AND METHODS 
 Participants 
 The study population has recently been described in detail 
( 25 ). Briefl y, participants for the present study were selected 
from two population-based longitudinal studies, FinnTwin16 
(FT16) and FinnTwin12 (FT12) ( 26 ). Twin pairs were enrolled 
for the present study based on their BMI in the last follow-up at 
young adult age. Twins were selected with the aim of covering the 
full BMI range of both normal-weight and obese subjects and a 
full range of within-pair differences in BMI ( D BMI). To best de-
scribe the effects of acquired obesity, all monozygotic (MZ) pairs 
from FT16 and FT12 and all dizygotic (DZ) pairs from FT16 who 
were discordant for obesity [intra-pair difference in BMI ( D BMI) 
 > 2.5 kg/m 2 ]; one twin obese subject (BMI   30) and the other 
cotwin nonobese subject were included in the study. In addition, 
random pairs were studied to obtain wide ranges of  D BMIs within 
pairs. In total, the present study included 121 twin pairs (46 MZ 
and 75 DZ) and of them, 21 MZ pairs and 48 DZ pairs were dis-
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lated with s-FGF21 levels ( r = 0.48,  P < 0.001) ( Fig. 1 A ), but 
not with s-Angptl3 levels ( r = 0.08,  P = 0.20) ( Fig. 1 B). 
Angptl3 and FGF21 serum levels showed no correlation 
with each other ( P > 0.68). 
 Angptl4 serum levels in MZ twin pairs 
 To assess the effect of acquired obesity on s-Angptl4 lev-
els, we compared the concentrations in MZ twins concor-
dant and discordant for BMI. Twins with an intra-pair 
difference in BMI greater than 2.5 kg/m 2 were considered 
discordant, and those with an intra-pair difference in BMI 
less than 2.5 kg/m 2 were considered concordant. Among 
discordant pairs, s-Angptl4 levels were signifi cantly de-
creased ( P = 0.04) in heavier twins (11 ng/ml, median; 
5–17 ng/ml, 25%–75% percentile; n = 21) compared with 
leaner twins (15 ng/ml, median; 7–27 ng/ml, 25%–75% 
percentile; n = 21) ( Fig. 2 A ). No differences were observed 
in concordant MZ twins ( Fig. 2 B). In contrast, s-Angptl3 
levels were not signifi cantly different in MZ twins discor-
dant or concordant for BMI ( P = 0.83 and 0.54, respec-
tively) ( Fig. 2 C, D). 
 Within-pair associations 
 Pearson correlations for the intra-pair differences ( D ) 
in s-Angptl4 levels were calculated for a number of rele-
vant phenotypes. Utilizing this procedure allowed exclud-
ing genetic infl uences in MZ twin pairs and partially 
controlling for them in DZ twin pairs, while controlling 
fully for shared familial (nongenetic) effects in both types 
of twins. As presented in  Table 1 ,  D s-Angptl4 was nega-
tively correlated with  D BMI ( r =  2 0.27,  P = 0.003) and 
 D Waist ( r =  2 0.21,  P = 0.01) and positively correlated with 
 D FGF21 ( r = 0.497,  P < 0.001). The observed correlations 
were independent of zygosity. 
 Genetic and environmental effects on Angptl4 
 Preliminary evidence for genetic infl uences on s-Angptl4 
levels was found in the slightly greater within-pair similar-
ity between MZ than between DZ cotwins. The correspond-
ing ICCs were: ICC-MZ = 0.21 (95% CI:  2 0.09–0.47), 
ICC-DZ = 0.17 (95% CI:  2 0.06–0.38). This initial estima-
tion was further confi rmed in the quantitative genetic 
analyses. Supported by preliminary univariate modeling, 
the bivariate Cholesky decomposition including s-FGF21 
resemblance in MZ twins with respect to DZ twins would be in-
dicative of potential genetic infl uences in the traits. This sugges-
tive evidence was confi rmed in subsequent biometric modeling. 
Accordingly, the variance in every trait was estimated to derive 
from the following different sources: additive genetic (labeled as 
A), refl ecting the summed effects of individual alleles over the 
loci; dominance genetic (D), refl ecting interactions between al-
leles at the same or different loci; common environmental (C), 
refl ecting the infl uence of factors that are shared by both cot-
wins; and individual-specifi c environmental (E) factors, which 
refl ect exposures that are not shared by the cotwins as well as 
measurement error (a random effect uncorrelated between 
twins). Hence, the overall genetic infl uence on the trait, also 
named heritability (broad sense), can be obtained by adding the 
estimates from A and D. 
 As a fi rst step, different univariate models were computed for 
FGF21, Angptl3, and Angplt4 to estimate the proportion of the 
total variance in a trait due to A, D, C, and E. Because only data 
from MZ and DZ twins reared together were available for this 
study, C and D infl uences could not be modeled together, and 
the possible hypothetical combinations of infl uences did not in-
clude them simultaneously (e.g., they were ADE, ACE, AE, CE, 
and E). Subsequently, a bivariate Cholesky decomposition was 
calculated entering both Angptl4 and FGF21 protein data, to es-
timate the extent to which infl uences identifi ed for Angptl4 were 
also present for FGF21. A full-information maximum likelihood 
method was applied in these procedures using individual-based 
observations. The simplest bivariate model that fi t the data best 
was chosen by comparing the fi t statistics [likelihood ratio test 
(LRT), as well as Akaike’s information criterion (AIC)] of the full 
model against those of the hierarchically nested models (those 
with fewer parameters estimated). 
 RESULTS 
 S-Angptl4 levels in all study subjects 
 In the total study population, s-Angptl4 levels ranged 
from 1 to 373 ng/ml, and the distribution was skewed to 
the left. Two clear outliers were identifi ed, having s-
Angptl4 concentration of 549 and 2,391 ng/ml. Although 
the values were reproduced in several measurements, no 
explanation could be identifi ed for these high values. In 
the whole-study population, s-Angptl4 levels were signifi -
cantly correlated only with serum FFAs ( r = 0.15,  P = 0.01), 
and this correlation was independent of gender, zygosity, 
or BMI. As expected, s-Angptl4 levels were strongly corre-
 Fig.  1. Correlation between serum concentration 
of Angptl4 and FGF21 (A), and Angptl4 and Angptl3 
(B) in all twins (n = 242). Concentrations were mea-
sured by specifi c ELISAs and analyzed by Pearson 
correlations after logarithmic transformation and 
corrected for clustered sampling. 
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 We also evaluated the impact of genetic and environ-
mental factors on s-Angptl3 levels. Higher ICC for MZ 
(0.40, 95% CI: 0.13–0.62) compared with DZ (0.13, 95% 
CI:  2 0.10–0.35) cotwins suggests that s-Angptl3 levels are 
in part genetically controlled. Heritability counted for 
35% of s-Angptl3 levels, with the remaining 65% attrib-
uted to specifi c environmental factors. Because of the 
lack of phenotypic correlation of s-Angptl3 with s-Angptl4 
or s-FGF21, no bivariate models were conducted for 
s-Angpltl3. 
 Adipose tissue Angptl4 mRNA expression levels and 
obesity in MZ twins 
 Adipose tissue Angptl4 (at- ANGPTL4 ) mRNA expres-
sion levels were obtained from genome-wide transcrip-
tome analysis performed in fat biopsies obtained from 44 
individual MZ twins. Affymetrix U133 Plus 2.0 chips con-
tain two probes for Angptl4 that gave almost-identical re-
sults ( r 2 = 0.92). We next compared the at- ANGPTL4 
expression levels in discordant and concordant MZ twins. 
In the discordant pairs, heavier twins exhibited signifi -
cantly ( P = 0.03) lower at- ANGPTL4 expression levels, as 
compared with their leaner cotwins ( Fig. 4 A ); whereas in 
concordant twins, similar expression levels were observed 
( Fig. 4 B). Pearson correlation analyses revealed that at-
 ANGPTL4 is negatively correlated with BMI ( r =  2 0.44,  P = 
0.001;  Fig. 5 A ), LDL-C ( r =  2 0.29,  P = 0.017), and fasting 
plasma glucose ( r =  2 0.25,  P = 0.044) and positively cor-
related with FFAs ( r = 0.36,  P = 0.016) and HDL-C ( r = 0.43, 
 P = 0.002;  Fig. 5 D) in individual twins. No signifi cant cor-
relations were observed between at- ANGPTL4 and fasting 
TG ( P = 0.67;  Fig. 5 E) or s-Angptl4 levels ( P = 0.94). In 
multivariate linear regression analyses including BMI, 
FFAs, LDL-C, HDL-C, and fasting plasma glucose, only 
BMI signifi cantly explains the at- ANGPTL4 ( Table 2 ). 
 Because Angptl4 was suggested to induce adipose tissue 
lipolysis, we investigated the association between at-
 ANGPTL4 and expression levels of several key players in-
volved in this process ( 29 ). Although the Affymetrix U133 
Plus 2.0 chip has one probe for  PNPLA2 [adipose triglycer-
ide lipase (ATGL)], for unknown reasons, the readouts 
were under the detection capacity of the Affymetrix system 
used and could not be analyzed. Expression levels for 
hormone-sensitive lipase ( LIPE ), monoglyceride lipase 
( MGLL ), G 0 /G 1 switch gene 2 ( G0S2 ), an ATGL inhibitor, 
and abhydrolase domain containing 5/gene identifi ca-
tion-58 ( ABHD5/CGI-58 ), an ATGL activator, were avail-
able and thus were analyzed against at- ANGPTL4 . Pearson 
correlations in individual twins showed that at- ANGPTL4 
expression levels are positively correlated with the mRNA 
expression levels of  LIPE ( r = 0.24,  P = 0.01;  Fig. 5 B) and 
 ABHD5/CGI-58 , ( r = 0.41,  P = 0.005;  Fig. 5 C) but not with 
 MGLL or  G0S2 ( P < 0.3). 
 DISCUSSION 
 Primed by our previous observation that s-Angptl4 is in-
versely correlated with obesity in a normal Finnish popula-
tion sample ( 13 ), in this study, we evaluated in more detail 
and s-Angptl4 suggested that an AE model including addi-
tive genetic (A) and specifi c environmental (E) effects best 
fi t the data. The heritability was 0.41 (95% CI: 0.21–0.57) 
for s-FGF21 and 0.19 (95% CI: 0.05–0.36) for s-Angptl4 
( Fig. 3 ). Importantly, these genetic infl uences on s-FGF21 
and s-Angptl4 levels were due to a common set of genes 
( r g = 1.0, 95% CI: 0.82–1.00), a phenomenon accounting 
for 37.2% (95% CI: 14.7–57.1) of the phenotypic correla-
tion between the traits ( r p = 0.75, 95% CI: 0.68–0.80). En-
vironmental factors were also highly shared by the traits 
( r e = 0.68, 95% CI: 0.56–0.77). 
 Fig.  2. Serum Angptl4 (A, B) and Angptl3 (C, D) levels in MZ 
twins discordant (A, C) and concordant (B, D) for obesity. Angptl4 
and Angptl3 concentration in serum was measured in 21 discordant 
and 25 concordant MZ pairs using established ELISAs. Data are pre-
sented as median ± interquartile range;  P values were calculated us-
ing paired  t -test after logarithmic transformation of the values. 
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 Functional studies in mice suggested two mechanisms 
for the infl uence of Angptl4 on measures of adiposity. 
First, Angptl4 seems to stimulate adipose tissue lipolysis ( 2, 
15 ) and second, Angptl4 appears to have an important 
role in the central regulation of energy metabolism by 
modulating AMPK activity in hypothalamus ( 3 ). Interest-
ingly, here we showed that at- ANGPTL4 expression levels 
are positively correlated with the adipose tissue hormone-
sensitive lipase ( LIPE ) and  CGI-58 gene expression, sup-
porting the notion that Angptl4 could promote adipose 
tissue lipolysis also in humans. However, defi nite conclu-
sions based on  LIPE mRNA levels must be made with cau-
tion, because it is well documented that hormone-sensitive 
lipase is regulated at the posttranslational level by phos-
phorylation ( 29 ). It is possible that reduction in at-Angptl4 
would promote white adipose tissue triglyceride storage, 
whereas increasing its expression would favor the lipolytic 
the relationship between Angptl4 and obesity-related pa-
rameters in a collection of young MZ and DZ twin pairs. 
 Most genetic studies have not identifi ed any association 
between  ANGPTL4 polymorphisms and obesity-related 
traits ( 18, 19, 30 ), with the exception of one study ( 31 ). 
Our results suggested that this may be partially due to the 
strong infl uence of environmental factors on Angptl4 pro-
tein and the relatively weak correlation between Angptl4 
and adiposity parameters. Furthermore, s-Angptl4 levels 
showed no correlation with BMI in all individual twins. 
However, when controlling for genetic infl uences, we ob-
served a signifi cant inverse correlation between s-Angptl4 
levels and BMI. Furthermore, in MZ twins, adipose tissue 
 ANGPTL4 (at- ANGPTL4 )  expression levels were also in-
versely correlated with BMI. Finally, both s-Angptl4 and 
at- ANGPTL4 expression levels were signifi cantly decreased 
in heavier twins compared with their leaner counterparts. 
 TABLE 1. Correlation of intra-pair differences in Angptl4 serum levels with intra-pair differences in clinical and 
biochemical parameters of MZ and DZ twins 
Parameter (intra-pair difference)
 D Angptl4
Pearson correlation Sig. (2-tailed) N
 D BMI  2 0.270  0.003 121
 D Waist  2 0.214  0.019 119
 D FFAs 0.140 0.14 112
 D Triglycerides  2 0.054 0.56 121
 D Cholesterol 0.004 0.96 121
 D LDL-C 0.005 0.96 117
 D HDL-C 0.038 0.68 121
 D Glucose  2 0.079 0.39 120
 D Insulin  2 0.134 0.16 114
 Fig.  3. Summary model of the best-fi tting bivariate Cholesky de-
composition representing the genetic and environmental architec-
ture between s-Angptl4 and FGF21. A indicates additive genetic 
infl uences, whereas E indicates specifi c environmental infl uences. 
Numbers on double-headed arrows correspond to the estimated 
genetic (top) and environmental correlations (bottom) between 
phenotypes. 
 Fig.  4. At- ANGPTL4 mRNA expression levels in discordant (A) 
and concordant (B) MZ twins. At- ANGPTL4 mRNA expression lev-
els were obtained from genome-wide transcriptome analysis per-
formed in fat biopsies from 17 discordant and 5 concordant MZ 
twins. Data are presented as median ± interquartile range;  P values 
were calculated using paired  t -test after logarithmic transformation 
of the values. 
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positively correlated with HDL-C ( 33 ). In the present 
study, we observed as well that at- ANGPTL4 expression 
correlates with HDL-C but not with triglycerides. These re-
sults seem to be in line with a recent genome-wide associa-
tion study performed in more than 100,000 individuals 
that revealed an association of variants in  ANGPTL4 with 
HDL-C but not with TGs ( 35 ). All these results support the 
hypothesis that the main lipoprotein parameter related to 
Angptl4 is HDL-C, not TG. How this observation can be 
reconciled with the inhibitory effect on LPL activity re-
mains to be clarifi ed. 
catabolism of cellular fat stores. Similar suggestions 
have recently been proposed by Koliwad et al. ( 32 ), who 
identifi ed Angptl4 as a potential key mediator of the 
effects of glucocorticoids on adipose tissue triglyceride 
homeostasis. 
 The relationship between Angptl4 and obesity seems to 
be very complex both in humans and in mice. Although 
we observed an inverse association between Angptl4 and 
body weight in young individuals, in an older population, 
the opposite relationship could be observed ( 33 ). Further-
more, Angptl4-null mice had impaired satiety generation 
and gained more weight when fed a normal diet but were 
resistant to diet-induced obesity ( 3 ). Other functions of 
Angptl4, such as the regulation of angiogenesis, could ex-
plain these discrepancies. Interestingly, the interplay be-
tween VEGFA and ANGPTL4 appears to mediate the 
increase in vascularization necessary for adipose tissue ex-
pansion ( 34 ). With current knowledge, it is diffi cult to 
draw a clear picture, and further studies are necessary to 
better understand the role of Angptl4 in obesity. 
 Although inhibition of LPL activity by Angptl4 and con-
sequent hypertriglyceridemia in mice is well established 
( 17 ), in our previous study in humans, we were not able to 
detect a correlation between s-Angptl4 and fasting TGs, 
whereas we successfully found that s-Angptl4 levels were 
 Fig.  5. Correlation between at- ANGPTL4 mRNA expression levels and obesity-related parameters: BMI (A), at- LIPE (B), and at- ABHD5 
(C). Correlations between at- ANGPTL4 levels and plasma lipid parameters: HDL (D) and triglycerides (E); in MZ twins, n = 44.  ANGPTL4 , 
LIPE , and  ABHD5 mRNA expression levels in adipose tissue (at- ANGPTL4 , at- LIPE , and at- ABHD5 , respectively) were measured from adi-
pose tissue biopsies using Affymetrix U133 Plus 2.0 array chips and normalized using GCRMA algorithm. Relationships between variables 
were analyzed by Pearson correlations after logarithmic transformation and corrected for clustered sampling.  P < 0.05 was considered 
signifi cant. 
 TABLE 2. Multivariate linear regression analyses between 
at- ANGPTL4 expression (dependent variable) and BMI, 
FFA, LDL-C, HDL-C, and glucose in MZ twins, n = 44 
Independent variable
Dependent variable: at- ANGPTL4 
expression
Regression coeffi cient  P a 
 BMI  2 32.6 ± 15  0.03 
FFAs 0.57 ± 0.4 0.19
LDL-C  2 193.2 ± 100 0.06
HDL-C  2 1.75 ± 2.15 0.99
Glucose  2 12.7 ± 127 0.92
 a P values are corrected for correlations of trait values of twins 
within pairs.
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 Human Angptl4 expression and secretion were previ-
ously shown to be increased by FFAs ( 28 ), and we observed 
that both of these parameters are signifi cantly correlated 
in serum samples derived from a general population ( 13 ). 
Also in this study, s-Angptl4 and FFAs were positively cor-
related. Furthermore, we observed a strong positive cor-
relation between s-Angptl4 and FGF21, another factor 
known to be regulated by FFAs through peroxisome prolif-
erator-activated receptor-dependent pathways ( 36 ). The 
strong relationship between Angptl4 and FGF21 is inter-
esting, inasmuch as both factors are potent regulators of 
energy metabolism and their concerted action could play 
an important role in adaptation to fasting ( 37 ). This no-
tion is also supported by our observation that both serum 
proteins share most genetic and environmental factors. 
 In summary, we have demonstrated that s-Angptl4 levels 
are modestly modulated by genetic factors and inversely 
correlated with measures of adiposity in humans. Our data 
support a role for Angptl4 in body fat regulation and sug-
gest that many of the observed effects in animal models 
are relevant in the context of human obesity.  
 The authors are thankful for the important contributions of all 
of the participants in the study and for the excellent technical 
assistance of Sari Nuutinen. 
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